皮 (Hypericum Scabrum) 提取物对大莱什曼病的抗莱什曼病活性
Reza Saberi1, Zaynab Jamshidzad2,3, Elaheh Karimi4
1Toxoplasmosis Research Center, Communicable Diseases Institute, School of Medicine, Mazandaran University of Medical Sciences, Sari, Iran.
AMB Express
|December 18, 2024
概括
这项研究研究了Hypericum scabrum提取物对Leishmania major.的抗莱什曼病作用. 植物提取物显示出显著的抑制活性,表明它有可能成为莱什曼病的新治疗方法.
科学领域:
- 药理学 药理学是指药理学的学科.
- 热带医学 热带医学
- 植物化学 植物化学
背景情况:
- 莱什曼病是一种重要的被忽视的热带疾病,治疗选择有限.
- 目前用于莱什曼病的治疗方法通常是有毒的,并且随着时间的推移而失去有效性.
- 迫切需要新的,安全和有效的抗莱什曼治疗方法.
研究的目的:
- 为了评估Hypericum scabrum (H. scabrum) 的水醇提取物的抗莱什曼病活性.
- 为了比较H. scabrum提取物与标准抗莱什曼病药物葡萄糖胺的疗效.
- 评估抑制作用对大莱什马尼亚的大型的前兆性形式的抑制作用.
主要方法:
- 从花朵和茎中制备的H. scabrum的酒提取物,使用化.
- 通过高性能液体染色学 (HPLC) 识别化学化合物.
- 使用MTT测定对L. major在不同度下进行评估的抗莱什曼性活性.
主要成果:
- 在72小时内,H. scabrum提取物对L.大促性菌的半最大抑制度 (IC50) 从85.11到245.47μg/ml不等.
- 与H. scabrum提取物相比,glucantime的IC50值较低 (12.58至30.19微克/毫升).
- 尽管H. scabrum提取物的疗效低于葡萄抗剂,但它在L. major上表现出显著的抑制作用.
结论:
- 皮草 (Hypericum scabrum) 提取物具有显著的抗莱什曼病特征,可以对抗莱什曼病主要的前列腺炎.
- 建议进行进一步的研究,包括动物模型研究,以探索H. scabrum对莱什曼病的治疗潜力.
- 这项研究支持对H. scabrum作为新抗莱什曼病药物开发的来源的调查.
关键词:
这就是Hypericum scabrum.莱什曼尼亚大型 (Leishmania major) 是一个很大的病.水醇提取物 含有水醇的提取物莱什曼病是一种莱什曼病.在MTT测试中使用MTT测试.更多相关视频
12:22A Parasite Rescue and Transformation Assay for Antileishmanial Screening Against Intracellular Leishmania donovani Amastigotes in THP1 Human Acute Monocytic Leukemia Cell Line
Published on: December 30, 2012
22.3K
06:57In Vivo Infection with Leishmania amazonensis to Evaluate Parasite Virulence in Mice
Published on: February 20, 2020
8.2K
相关概念视频
Leishmaniasis
Leishmaniasis is a protozoal disease caused by species of the genus Leishmania and transmitted through the bite of infected female sandflies. The parasite exists in two principal morphological forms during its life cycle. A sandfly acquires intracellular amastigotes from an infected reservoir host, such as a dog. Within the sandfly, these forms differentiate into motile, flagellated promastigotes. During a subsequent blood meal, promastigotes are injected into the human host, where they...
Antiprotozoal Agents
Leishmaniasis is a widespread parasitic disease caused by several Leishmania species. It affects millions of people each year and remains a major public health problem in endemic regions. First-line treatment relies on pentavalent antimonials, including meglumine antimoniate and sodium stibogluconate. Even so, how these drugs work has not been fully clear, especially their interaction with parasite-specific biochemical pathways. One key target is trypanothione reductase (TR), an enzyme that...
